Initial assessment of the role of CXC chemokine receptor 4 after polytrauma

Molecular Medicine

Volumn 18, Issue 7, 2012, Pages 1056-1066

  Bach IV, Harold H ^a   Saini, Vikas ^a   Baker, Todd A ^a   Tripathi, Abhishek ^a   Gamelli, Richard L ^a   Majetschak, Matthias ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; INTERLEUKIN 6; STROMAL CELL DERIVED FACTOR 1ALPHA; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CELL COUNT; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE MIGRATION; MALE; MOLECULAR PATHOLOGY; MULTIPLE TRAUMA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RECEPTOR UPREGULATION;

ANIMALS; FEMALE; HETEROCYCLIC COMPOUNDS; INTERLEUKIN-6; LEUKOCYTE COUNT; LIPOPOLYSACCHARIDES; MALE; PROTEIN BINDING; RECEPTORS, CELL SURFACE; RECEPTORS, CXCR4; SUS SCROFA; TEICHOIC ACIDS; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITIN; WOUNDS AND INJURIES;

EID: 84866751261     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00497     Document Type: Article

References (69)

1. Regard JB, Sato IT, Coughlin SR. (2008) Anatomical profiling of G protein-coupled receptor expression. Cell. 135:561-71.
2. Busillo JM, Benovic JL. (2007) Regulation of CXCR4 signaling. Biochim. Biophys. Acta. 1768:952-963.
3. Nagasawa T, et al. (1996) Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 382:635-8.
4. Tachibana K, et al. (1998) The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature. 393:591-4.
5. Karin N. (2010) The multiple faces of CXCL12 (SDF-1alpha) in the regulation of immunity during health and disease. J. Leukoc. Biol. 88:463-73.
6. Zaruba MM, Franz WM. (2010) Role of the SDF-1-CXCR4 axis in stem cell-based therapies for ischemic cardiomyopathy. Expert Opin. Biol. Ther. 10:321-35.
7. Li M, et al. (2010) CXCR4+ progenitors derived from bone mesenchymal stem cells differentiate into endothelial cells capable of vascular repair after arterial injury. Cell Reprogram. 12:405-15.
8. Nagasawa T, Tachibana K, Kishimoto T. (1998) A novel CXC chemokine PBSF/SDF-1 and its receptor CXCR4: their functions in development, hematopoiesis and HIV infection. Semin. Immunol. 10:179-85.
9. Veldkamp CT, Ziarek JJ, Peterson FC, Chen Y, Volkman BF. (2010) Targeting SDF-1/CXCL12 with a ligand that prevents activation of CXCR4 through structure-based drug design. J. Am. Chem. Soc. 132:7242-3.
10. Teicher BA, Fricker SP. (2010) CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin. Cancer Res. 16:2927-31.
11. Bleul CC, et al. (1996) The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature. 382:829-33.
12. Saini V, Marchese A, Majetschak M. (2010) CXC chemokine receptor 4 is a cell surface receptor for extracellular ubiquitin. J. Biol. Chem. 285: 15566-76.
13. Saini V, Marchese A, Tang WJ, Majetschak M. (2011) Structural determinants of the ubiquitin-CXC chemokine receptor 4 interaction. J. Biol. Chem. 286:44145-52.
14. Saini V, Romero J, Marchese A, Majetschak M. (2010) Ubiquitin receptor binding and signaling in primary human leukocytes. Commun. Integr. Biol. 3:608-10.
15. Saini V, et al. (2011) The CXC chemokine receptor 4 ligands ubiquitin and stromal cell-derived factor-111function through distinct receptor interactions. J. Biol. Chem. 286:33466-77.
16. Majetschak M, et al. (2003) Extracellular ubiquitin inhibits the TNF-alpha response to endotoxin in peripheral blood mononuclear cells and regulates endotoxin hyporesponsiveness in critical illness. Blood. 101:1882-90.
17. Majetschak M, et al. (2008) Systemic ubiquitin release after blunt trauma and burns: association with injury severity, posttraumatic complications, and survival. J. Trauma. 64:586-96.
18. Majetschak M. (2011) Extracellular ubiquitin: immune modulator and endogenous opponent of damage-associated molecular pattern molecules. J. Leukoc. Biol. 89:205-19.
19. Fan H, et al. (2012) Beneficial effect of a CXCR4 agonist in murine models of systemic inflammation. Inflammation. 35:130-7.
20. Kanki S, et al. (2011) Stromal cell-derived factor-1 retention and cardioprotection for ischemic myocardium. Circ. Heart Fail. 4:509-18.
21. Hu X, et al. (2007) Stromal cell derived factor-1 alpha confers protection against myocardial ischemia/reperfusion injury: role of the cardiac stromal cell derived factor-1 alpha CXCR4 axis. Circulation. 116:654-63.
22. Meiron M, Zohar Y, Anunu R, Wildbaum G, Karin N. (2008) CXCL12 (SDF-1alpha) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen-specific regulatory T cells. J. Exp. Med. 205:2643-55.
23. Garcia-Covarrubias L, Manning EW 3rd, Sorell LT, Pham SM, Majetschak M. (2008) Ubiquitin enhances the Th2 cytokine response and attenuates ischemia-reperfusion injury in the lung. Crit. Care Med. 36:979-82.
24. Majetschak M, et al. (2004) Effects of exogenous ubiquitin in lethal endotoxemia. Surgery. 135:536-43.
25. Majetschak M, Cohn SM, Obertacke U, Proctor KG. (2004) Therapeutic potential of exogenous ubiquitin during resuscitation from severe trauma. J. Trauma. 56:991-9.
26. Earle SA, et al. (2006) Prolongation of skin graft survival by exogenous ubiquitin. Transplantation. 82:1544-6.
27. Earle SA, Proctor KG, Patel MB, Majetschak M. (2005) Ubiquitin reduces fluid shifts after traumatic brain injury. Surgery. 138:431-8.
28. Griebenow M, Casalis P, Woiciechowsky C, Majetschak M, Thomale UW. (2007) Ubiquitin reduces contusion volume after controlled cortical impact injury in rats. J. Neurotrauma. 24:1529-35.
29. Ahn HC, et al. (2009) Ischemia-related changes in naive and mutant forms of ubiquitin and neuroprotective effects of ubiquitin in the hippocampus following experimental transient ischemic damage. Exp. Neurol. 220:120-32.
30. Baker TA, et al. (2012) Effects of exogenous ubiquitin in a polytrauma model with blunt chest trauma. Crit. Care Med. 40:2376-84.
31. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. (1998) Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature. 393:595-9.
32. Ryu KY, et al. (2007) The mouse polyubiquitin gene UbC is essential for fetal liver development, cell-cycle progression and stress tolerance. EMBO J. 26:2693-706.
33. Hatse S, Princen K, Bridger G, De Clercq E, Schols D. (2002) Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett. 527:255-62.
34. Fricker SP, et al. (2006) Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochem. Pharmacol. 72:588-96.
35. Zhang WB, et al. (2002) A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J. Biol. Chem. 277:24515-21.
36. Brave M, et al. (2010) FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Oncology. 78:282-8.
37. Patel MB, Proctor KG, Majetschak M. (2006) Extracellular ubiquitin increases in packed red blood cell units during storage. J. Surg. Res. 135:226-32.
38. Committee for the Update of the Guide for the Care and Use of Laboratory Animals, Institute for Laboratory Animal Research, Division on Earth and Life Studies, National Research Council of the National Academies. (2011) Guide for the Care and Use of Laboratory Animals. 8th edition. Washington (DC): National Academies Press. [cited 2012 Aug 10]. Available from: http://oacu. od.nih.gov/regs/
39. Dudkiewicz M, Harpaul TA, Proctor KG. (2008) Hemoglobin-based oxygen carrying compound-201 as salvage therapy for severe neuro-and polytrauma (Injury Severity Score = 27-41). Crit. Care Med. 36:2838-48.
40. Baker TA, et al. (2011) Systemic release of cytokines and heat shock proteins in porcine models of polytrauma and hemorrhage. Crit. Care Med. 40:876-85.
41. Greenspan L, McLellan BA, Greig H. (1985) Abbreviated Injury Scale and Injury Severity Score: a scoring chart. J. Trauma. 25:60-4.
42. Hendrix CW, et al. (2000) Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob. Agents Chemother. 44:1667-73.
43. Boyum A. (1968) Isolation of mononuclear cells and granulocytes from human blood: isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab. Invest. Suppl. 97:77-89.
44. Majetschak M, et al. (2008) Cardiac proteasome dysfunction during cold ischemic storage and reperfusion in a murine heart transplantation model. Biochem. Biophys. Res. Commun. 365:882-8.
45. Geng Q, et al. (2009) A subset of 26S proteasomes is activated at critically low ATP concentrations and contributes to myocardial injury during cold ischemia. Biochem. Biophys. Res. Commun. 390:1136-41.
46. Fricker SP, et al. (2006) Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochem. Pharmacol. 72:588-96.
47. Hesselgesser J, et al. (1998) Identification and characterization of the CXCR4 chemokine receptor in human T cell lines: ligand binding, biological activity, and HIV-1 infectivity. J. Immunol. 160:877-83.
48. Loetscher P, Gong JH, Dewald B, Baggiolini M, Clark-Lewis I. (1998) N-terminal peptides of stromal cell-derived factor-1 with CXC chemokine receptor 4 agonist and antagonist activities. J. Biol. Chem. 273:22279-83.
49. Bernhagen J, et al. (2007) MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat. Med. 13:587-96.
50. Di Salvo J, et al. (2000) The CXCR4 agonist ligand stromal derived factor-1 maintains high affinity for receptors in both Galpha(i)-coupled and uncoupled states. Eur. J. Pharmacol. 409:143-54.
51. Hesselgesser J, et al. (1997) CD4-independent association between HIV-1 gp120 and CXCR4: functional chemokine receptors are expressed in human neurons. Curr. Biol. 7:112-21.
52. Liles WC, et al. (2003) Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood. 102:2728-30.
53. Hubel K, et al. (2004) Leukocytosis and mobilization of CD34+ hematopoietic progenitor cells by AMD3100, a CXCR4 antagonist. Support Cancer Ther. 1:165-72.
54. Broxmeyer HE, et al. (2005) Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J. Exp. Med. 201:1307-18.
55. Dar A, et al. (2011) Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells. Leukemia. 25:1286-96.
56. Majetschak M, et al. (2005) Ubiquitin immunoreactivity in cerebrospinal fluid after traumatic brain injury: clinical and experimental findings. Crit. Care Med. 33:1589-94.
57. Hattori K, et al. (2001) Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood. 97:3354-60.
58. Muller HC, et al. (2010) Simvastatin attenuates ventilator-induced lung injury in mice. Crit. Care. 14:R143.
59. Triantafilou M, et al. (2008) Chemokine receptor 4 (CXCR4) is part of the lipopolysaccharide "sensing apparatus. " Eur. J. Immunol. 38:192-203.
60. Hajishengallis G, Wang M, Liang S, Triantafilou M, Triantafilou K. (2008) Pathogen induction of CXCR4/TLR2 cross-talk impairs host defense function. Proc. Natl. Acad. Sci. U. S. A. 105:13532-37.
61. Balabanian K, et al. (2005) The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J. Biol. Chem. 280:35760-6.
62. Kalatskaya I, et al. (2009) AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol. Pharmacol. 75:1240-7.
63. Kim HY, et al. (2010) The CXCR4 antagonist AMD3100 has dual effects on survival and proliferation of myeloma cells in vitro. Cancer Res. Treat. 42:225-34.
64. Wu B, et al. (2010) Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science. 330:1066-71.
65. Gravel S, et al. (2010) The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains. J. Biol. Chem. 285:37939-43.
66. Moomey CB Jr, Melton SM, Croce MA, Fabian TC, Proctor KG. (1999) Prognostic value of blood lactate, base deficit, and oxygen-derived variables in an LD50 model of penetrating trauma. Crit. Care Med. 27:154-61.
67. Cerovic O, Golubovic V, Spec-Marn A, Kremzar B, Vidmar G. (2003) Relationship between injury severity and lactate levels in severely injured patients. Intensive Care Med. 29:1300-5.
68. Abramson D, et al. (1993) Lactate clearance and survival following injury. J. Trauma. 35:584-8.
69. Manikis P, Jankowski S, Zhang H, Kahn RJ, Vincent JL. (1995) Correlation of serial blood lactate levels to organ failure and mortality after trauma. Am. J. Emerg. Med. 13:619-22.